Foghorn Therapeutics Inc.

FHTXNASDAQHealthcare● Active

$3.71

$-0.02(-0.54%)

Market Cap$217828569

P/E Ratio—

52W High$6.95

52W Low$3.27

Avg Volume159K

Open$3.67

Beta2.89

Free Cash Flow Financials Revenue

Foghorn Therapeutics Inc. (FHTX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

FHTX · free cash flow · updated Jun 9, 2026

Core FCF metrics

FHTX · FCF · TTM · margin & CAGR

Free cash flow was −$86.1M for FY2025 (fiscal year ending 2025-12-31), up 15.0% year-over-year The FCF margin was -278.7%.

FY2025 Free Cash Flow−$86.1M▲ +15.0% YoY

Trailing 12M (TTM)−$87.4Mtrailing 4 quarters sum

FCF Margin-278.7%−$86.1M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

FHTX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$86.1M(0M)−$86.1M▲ +15.0%-278.7%

FY2024−$100.4M(1M)−$101.3M▲ +15.1%-448.2%

FY2023−$118.1M(1M)−$119.3M▼ 162.0%-349.4%

FY2022$193.6M(1M)$192.4M▲ +459.2%—

FY2021−$50.3M(3M)−$53.6M▼ 12.8%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

FHTX · P/FCF · FCF yield · FCF per share

Foghorn Therapeutics Inc. (FHTX) reported negative free cash flow of −$0.09B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

FHTX · cash flow statement · operating / investing / financing

For FY2025, Foghorn Therapeutics Inc. generated −$86.1M in operating cash flow and spent 0M in capital expenditures, yielding −$86.1M in free cash flow.

Operating Activities

−$86.1M

Cash from core business operations

2025-12-31

Investing Activities

+$112.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$1.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$86.1M) − |CapEx| (0M) = FCF (−$86.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

FHTX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Foghorn Therapeutics Inc.YOU

FHTX

−$86.1M+15.0%-278.7%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Foghorn Therapeutics Inc. (FHTX) reported free cash flow of −$86.1M for FY2025 (fiscal year ending 2025-12-31), up 15.0% year-over-year. The FCF margin was -278.7%.

Based on available data, Foghorn Therapeutics Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $192.4M in FY2022.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

FHTX free cash flow · 8 questions

Foghorn Therapeutics Inc. free cash flow was −$86.1M for FY2025, up 15.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$87.4M.

FHTX free cash flowFHTX FCFFHTX FCF 2025FHTX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Foghorn Therapeutics Inc. · Foghorn Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026